What is Zacks Small Cap’s Forecast for COCP Q1 Earnings?

Cocrystal Pharma, Inc. (NASDAQ:COCP) – Equities research analysts at Zacks Small Cap issued their Q1 2025 earnings per share (EPS) estimates for Cocrystal Pharma in a report released on Tuesday, April 1st. Zacks Small Cap analyst D. Bautz forecasts that the company will earn ($0.41) per share for the quarter. The consensus estimate for Cocrystal Pharma’s current full-year earnings is ($1.85) per share. Zacks Small Cap also issued estimates for Cocrystal Pharma’s Q2 2025 earnings at ($0.44) EPS, FY2025 earnings at ($1.65) EPS and FY2026 earnings at ($1.42) EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Cocrystal Pharma in a report on Wednesday, January 22nd.

Cocrystal Pharma Price Performance

Shares of NASDAQ COCP opened at $1.43 on Thursday. The stock has a market capitalization of $14.55 million, a P/E ratio of -0.77 and a beta of 2.35. Cocrystal Pharma has a one year low of $1.35 and a one year high of $3.26. The firm’s 50 day simple moving average is $1.77 and its two-hundred day simple moving average is $1.92.

Cocrystal Pharma (NASDAQ:COCP) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.23.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.